Spero Therapeutics Inc. (SPRO)
SPRO trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price · October 14, 2026
$1.15
-2.54% on the day
Market cap
$67.0M
Micro cap
Revenue · 2025
$66.8M
+39.2% on 2024
Net income · 2025
$8.6M
12.8% net margin
Price, change, market cap, sector and industry: Nasdaq stock screener, as of October 14, 2026. Revenue: SEC XBRL frames, calendar 2025.
Profile
| Field | Value |
|---|---|
| Ticker | SPRO on Nasdaq |
| Sector | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Country | United States |
| IPO year | 2017 |
| SEC CIK | 0001701108 |
| SEC industry code | Pharmaceutical Preparations |
| Incorporated in | DE |
Financials · 2025
| Line | Value |
|---|---|
| Revenue | $66.8M |
| Net income | $8.6M |
| Operating income | $6.3M |
| Net margin | 12.8% |
| Operating margin | 9.5% |
| Revenue growth | +39.2% |
| Cash | $40.3M |
| Total assets | $68.9M |
| P/E (computed) | 7.8× |
| P/S (computed) | 1.0× |
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document | S-3 | 2026-08-28 |
| Latest annual report | 10-K | 2026-03-26 |
| Latest quarterly / interim | 10-Q | 2026-08-12 |
| Latest current report | 8-K | 2026-08-28 |
| Latest proxy | DEFA14A | 2026-04-27 |
Source: SEC EDGAR submissions feed, 513 recent filings. All filings on EDGAR.
Peers in Biotechnology: Pharmaceutical Preparations
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| OSTX | OS Therapies Incorporated | $1.45 | -7.05% | $67.4M |
| XBIT | XBiotech Inc. | $2.16 | -5.68% | $65.9M |
| CING | Cingulate Inc. | $4.72 | -2.48% | $68.6M |
| RNTX | Rein Therapeutics Inc. | $0.7546 | -3.86% | $65.1M |
| NMAD | Nomad Power Solutions Inc. | $4.28 | +2.64% | $68.9M |
| FBIO | Fortress Biotech Inc. | $1.95 | -7.58% | $65.0M |
| SDEV | Stablecoin Development Corporation | $1.25 | -11.35% | $64.7M |
| HYFT | MindWalk Holdings Corp. | $1.48 | +5.71% | $69.7M |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier